Replacing Foods with a High-Glycemic Index and High in Saturated Fat by Alternatives with a Low Glycemic Index and Low Saturated Fat Reduces Hepatic Fat, Even in Isocaloric and Macronutrient Matched Conditions.

adults with overweight and obesity de novo lipogenesis dietary intervention heavy water liver glycogen magnetic resonance spectroscopy

Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
01 Feb 2023
Historique:
received: 12 12 2022
revised: 27 01 2023
accepted: 29 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Current guidelines aim to limit the dietary glycemic index (GI) and intake of saturated fatty acids (SFA). Several studies have shown favorable effects of low-GI or low-SFA diets on intrahepatic lipid content (IHL), but these studies were performed under overfeeding conditions or extreme differences in GI or SFA to maximize the contrast between diets. By combining changes in GI and SFA, we can mimic how people can improve their diet in a realistic setting. We investigated the effect on liver fat content and substrate metabolism of both reducing GI and replacing SFA with polyunsaturated fat in practically realistic amounts under isocaloric conditions. In a randomized crossover study, thirteen overweight participants consumed two diets, one high in GI and SFA (high GI/SFA) and one low in GI and SFA (low GI/SFA) with identical macronutrient composition, for two weeks each. Diets were equal in caloric content, consisted of habitual food items, and had a macronutrient composition that can be easily achieved in daily life. At the end of each intervention, IHL content/composition and liver glycogen were measured by magnetic resonance spectroscopy. Additionally, fasted and postprandial hepatic de novo lipogenesis and glycemic and metabolic responses were investigated. IHL was significantly lower (-28%) after the two-week low-GI/SFA diet (2.4 ± 0.5% 95% CI [1.4, 3.4]) than after the two-week high-GI/SFA diet (3.3 ± 0.6% 95% CI [1.9, 4.7], Changes in macronutrient quality can already have drastic effects on liver fat content and postprandial glycemia after two weeks and even when energy content and the percentage of total fat and carbohydrate remains unchanged.

Sections du résumé

BACKGROUND BACKGROUND
Current guidelines aim to limit the dietary glycemic index (GI) and intake of saturated fatty acids (SFA). Several studies have shown favorable effects of low-GI or low-SFA diets on intrahepatic lipid content (IHL), but these studies were performed under overfeeding conditions or extreme differences in GI or SFA to maximize the contrast between diets. By combining changes in GI and SFA, we can mimic how people can improve their diet in a realistic setting.
OBJECTIVES OBJECTIVE
We investigated the effect on liver fat content and substrate metabolism of both reducing GI and replacing SFA with polyunsaturated fat in practically realistic amounts under isocaloric conditions.
DESIGN AND METHODS METHODS
In a randomized crossover study, thirteen overweight participants consumed two diets, one high in GI and SFA (high GI/SFA) and one low in GI and SFA (low GI/SFA) with identical macronutrient composition, for two weeks each. Diets were equal in caloric content, consisted of habitual food items, and had a macronutrient composition that can be easily achieved in daily life. At the end of each intervention, IHL content/composition and liver glycogen were measured by magnetic resonance spectroscopy. Additionally, fasted and postprandial hepatic de novo lipogenesis and glycemic and metabolic responses were investigated.
RESULTS RESULTS
IHL was significantly lower (-28%) after the two-week low-GI/SFA diet (2.4 ± 0.5% 95% CI [1.4, 3.4]) than after the two-week high-GI/SFA diet (3.3 ± 0.6% 95% CI [1.9, 4.7],
CONCLUSIONS CONCLUSIONS
Changes in macronutrient quality can already have drastic effects on liver fat content and postprandial glycemia after two weeks and even when energy content and the percentage of total fat and carbohydrate remains unchanged.

Identifiants

pubmed: 36771441
pii: nu15030735
doi: 10.3390/nu15030735
pmc: PMC9920748
pii:
doi:

Substances chimiques

Fatty Acids 0
Dietary Fats 0
Dietary Carbohydrates 0

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Health Holland
ID : LSHM15039

Références

J Clin Endocrinol Metab. 2019 Dec 1;104(12):6207-6219
pubmed: 31369090
Br J Nutr. 2004 Feb;91(2):245-52
pubmed: 14756910
Int J Obes Relat Metab Disord. 2002 Jun;26(6):814-21
pubmed: 12037652
Clin Nutr. 2013 Jun;32(3):346-52
pubmed: 23111004
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Am J Clin Nutr. 2002 Jul;76(1):5-56
pubmed: 12081815
Diabetologia. 2022 Oct;65(10):1710-1720
pubmed: 35871650
Br J Nutr. 2013 Mar 28;109(6):1096-104
pubmed: 22849970
Gut. 2021 May;70(5):962-969
pubmed: 32938692
Acta Physiol Pharmacol Neerl. 1957;6:795-802
pubmed: 13487422
Am J Clin Nutr. 1985 Nov;42(5):769-77
pubmed: 3933323
Proc Natl Acad Sci U S A. 1918 Dec;4(12):370-3
pubmed: 16576330
Metabolism. 2021 Feb;115:154455
pubmed: 33259835
Diabetes. 2014 Jul;63(7):2356-68
pubmed: 24550191
J Appl Physiol (1985). 1997 Dec;83(6):2064-72
pubmed: 9390982
Hepatol Int. 2013 Dec;7 Suppl 2:765-70
pubmed: 26202292
BMJ Open Diabetes Res Care. 2020 Mar;8(1):
pubmed: 32188593
Nutrients. 2013 May 10;5(5):1544-60
pubmed: 23666091
Am J Clin Nutr. 2000 Oct;72(4):905-11
pubmed: 11010930
Metabolism. 1996 Jul;45(7):817-21
pubmed: 8692014
Nat Commun. 2020 Apr 20;11(1):1891
pubmed: 32312974
Metabolism. 1988 Feb;37(2):145-51
pubmed: 3123874
Diabetes Obes Metab. 2017 Jan;19(1):70-77
pubmed: 27593525
Cell Metab. 2018 Mar 6;27(3):559-571.e5
pubmed: 29456073
J Clin Endocrinol Metab. 2005 May;90(5):2804-9
pubmed: 15741262
J Lipid Res. 1999 Dec;40(12):2322-32
pubmed: 10588958
J Clin Endocrinol Metab. 2011 Apr;96(4):E691-5
pubmed: 21252252
Ann Intern Med. 2023 Jan;176(1):10-21
pubmed: 36508737
Nutrients. 2022 Feb 08;14(3):
pubmed: 35277067
Diabetes. 2005 Sep;54(9):2694-701
pubmed: 16123359
Nutrition. 1993 Sep-Oct;9(5):480-91; discussion 480, 492
pubmed: 8286893
J Physiol. 1949 Aug;109(1-2):1-9
pubmed: 15394301
Br J Nutr. 2012 Oct;108(7):1286-91
pubmed: 22176632
Diabetes Care. 2018 Aug;41(8):1732-1739
pubmed: 29844096
Obesity (Silver Spring). 2014 Aug;22(8):1854-9
pubmed: 24890344
J Clin Endocrinol Metab. 2012 Dec;97(12):E2288-92
pubmed: 23015656
Am J Clin Nutr. 2012 Oct;96(4):727-34
pubmed: 22952180
Diabetes Care. 2020 May;43(5):1134-1141
pubmed: 32165444
Am J Clin Nutr. 1988 Aug;48(2):240-7
pubmed: 3165600
Am J Clin Nutr. 2011 May;93(5):1048-52
pubmed: 21367948
Am J Clin Nutr. 2012 May;95(5):1003-12
pubmed: 22492369
J Clin Invest. 2005 May;115(5):1343-51
pubmed: 15864352
Med Sci Sports Exerc. 1995 Dec;27(12):1692-7
pubmed: 8614327
Aliment Pharmacol Ther. 2018 Jan;47(2):268-278
pubmed: 29115682

Auteurs

Jeremy Basset-Sagarminaga (J)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Kay H M Roumans (KHM)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Bas Havekes (B)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

Ronald P Mensink (RP)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Harry P F Peters (HPF)

Unilever Food Innovation Center, Plantage 14, 6708 WJ Wageningen, The Netherlands.

Peter L Zock (PL)

Unilever Food Innovation Center, Plantage 14, 6708 WJ Wageningen, The Netherlands.

Renée de Mutsert (R)

Department of Clinical Epidemiology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

Jan Borén (J)

Department of Molecular and Clinical Medicine, University of Gothenburg, P.O. Box 428, 40530 Gothenburg, Sweden.

Lucas Lindeboom (L)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.

Patrick Schrauwen (P)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.

Vera B Schrauwen-Hinderling (VB)

Department of Nutrition and Movement Sciences, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, 40225 Düsseldorf, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH